Heidelberg Pharma has been granted a patent for humanized antibodies targeting Prostate Specific Membrane Antigen (PSMA) for treating prostate cancer and other diseases. The antibodies have specific sequences for binding to PSMA, offering potential therapeutic benefits in neoplastic and neurological conditions. GlobalData’s report on Heidelberg Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Heidelberg Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Heidelberg Pharma's grant share as of May 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized antibody for treating prostate cancer and other diseases
A recently granted patent (Publication Number: US11976131B2) discloses a humanized antibody designed to target the extracellular domain of prostate-specific membrane antigen (PSMA). The antibody comprises specific sequences in its variable heavy (VH) and variable light (VL) domains, ensuring binding to PSMA. The patent claims cover various configurations of the VH and VL domains, with specific CDR sequences and homology requirements outlined for each domain. Additionally, the patent includes claims related to glycosylation, isotype, and antigen-binding fragments of the humanized antibody.
Furthermore, the patent extends to applications beyond the antibody itself, including antibody-drug conjugates (ADCs), pharmaceutical formulations, and methods of treating prostate cancer using the disclosed humanized antibody. The patent also encompasses nucleic acids encoding the antibody and host cells capable of producing it. Overall, the patent provides a comprehensive protection for the humanized antibody targeting PSMA, offering potential therapeutic benefits for patients suffering from prostate cancer.
To know more about GlobalData’s detailed insights on Heidelberg Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
